Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024. In the quarter to June 2026, revenue grew 22.5%, EPS grew 500.0% and free cash flow grew 17,503.7%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow VCEL
Vericel Corporation (VCEL) P/E ratio
As of 16 October 2026, Vericel Corporation (VCEL) trades at a P/E ratio of 83.6×. Over the past ten years it has ranged from 0.0× (June 2024) to 5,356× (August 2024); the current reading is higher than 70% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 113× | (59.01%) |
| FY2024 | 275× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 441× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 92.7× | 23.89% |
| Mar 2026 | 74.8× | (33.52%) |
| Dec 2025 | 113× | (7.03%) |
| Sep 2025 | 121× | (60.18%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NVAX Novavax, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| VRDN Viridian Therapeutics, Inc. compare | n/m |
| PHVS Pharvaris N.V. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.9× |
| VCEL Vericel Corporation | 83.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)